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Nanomedicine intends to create and fur-
ther use novel materials at the nanoscale
in order to provide an improvement
upon current medical applications for
human healthcare (ESF, 2005; Etheridge
et al., 2013). In line with the advances
made within nanotechnology since the
late twentieth century (Mamalis, 2007)
nanomedicine has received heightened
attention due to its potential advantages,
most notably within (cancer) theranostics
(Muthu et al., 2014). The field of theranos-
tics aims to utilize the physico-chemical
characteristics of nanosized materials in
order to intensify the effectiveness in
diagnosing and treating diseases at the
molecular level (Kim et al., 2013). Such
a perspective is notably paramount for
cancer types that are difficult to iden-
tify as well as apply therapy toward (e.g.,
secondary cancer) (Muthu et al., 2014).
Despite the well documented and pro-
posed benefits of therapeutics in the nano-
size range (Krol et al., 2013), for the
majority of nanoparticles (NPs) [defined
as “a nano-object with all three dimen-
sions in the nanoscale (1–100 nm)′′ (BSI,
2007; ISO 27687, 2008)], the ability to
merge the expansive divide between devel-
oping a significant advancement within
material science and creating a biologi-
cally relevant therapeutic has proven to
be a highly non-trivial task. One impor-
tant reason for this is the relatively limited
specific understanding of the biological
interaction of therapeutic NPs following
their administration into the human body
and their subsequent delivery to the target
site (e.g., tumor) (Capco and Chen, 2014).
The objective of this opinion article there-
fore, is to provide a biological perspec-
tive upon what must be considered in the
development of theranostic NPs.
WHERE SHOULD FOCUS BE GIVEN?
For biologically effective theranostic
NPs, determining their dispersity, bio-
compatibility and biostability within
different biological environments is
imperative. For this, an understanding
of the dynamic interaction between NPs
with liquid and cellular systems as well
as their subsequent biological impact
must be gained. This outlook is not
straight-forward and requires an intensive,
multi-interdisciplinary research focus with
cross-talk/feedback loops between the
material scientists developing the mate-
rials and the biologists/clinicians wishing
to study/apply them.
Initially, from a material perspective,
there are an abundance of complex hurdles
that must be overcome when developing
any proposed nanotheranostic (Petros and
DeSimone, 2010). Whether the NPs are
manufactured for use as a treatment e.g.,
degenerative disease states (e.g., Alzheimer
disease) (Liu et al., 2005), infectious dis-
eases (e.g., hepatitis B) (Li et al., 2010)
cancer (McMillan et al., 2014), or as a
diagnostic tool (Niemirowicz et al., 2012),
a systematic chemistry approach must be
used (Davis et al., 2008). Whilst the spe-
cific shape of the NPs is of extreme interest
regarding their efficiency as a theranostic
agent (Liu et al., 2012), it is the precise
material applied that is important, as well
as the surface layer and the subsequent
surface attachment of therapeutic agents
and additional molecules (e.g., fluo-
rophores, receptor-targetting moieties)
to the modality (Petros and DeSimone,
2010), while keeping within the nano-
size range. Additionally, determining their
dispersity (i.e., colloidal stability) and
biostability can also be laborious and
problematic (Petros and DeSimone, 2010).
Although these issues are not trivial, once
the NP is engineered and ready for use, one
of the main, biologically-based obstacles
is to determine the ease of directing this
modality to the site of interest within the
human body without causing any unde-
sirable effects (e.g., recognition and/or
clearance by the immune system).
Successful targeting of theranostic NPs
is an onerous concept (Nicolaides et al.,
2014), and is commonly overlooked in
favor of immediately focussing upon the
effectiveness of the theranostic agent upon
the specific target site (i.e., cancer cells for
cancer therapeutics) (Xie et al., 2011). For
example, a plethora of studies have been
published which have shown the effective-
ness of theranostic NPs in either the deliv-
ery of a drug to cells (Najafi et al., 2014),
or destructing cancer cells with or with-
out external stimuli (e.g., light, magnetic
field) (Hayashi et al., 2014). Naturally, this
approach is of extreme importance, and
absolutely vital toward the development
of any theranostic based NPs. However,
the precise effective nature (i.e., efficacy)
of the NPs upon the chosen target site
can be considered as inextricably linked to
the efficient transport of NPs from their
administration site into the human body
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to the specifically chosen target site (Davis
et al., 2008). Therefore it is essential that
the interpretation of the effectiveness of
theranostic NPs directly upon the target
site is considered after gaining a controlled
understanding of the biological impact
upon the NPs following their transport
through different biological environments
to said target site.
Thus, in order to fully elucidate the
impact of the transport processes fol-
lowing administration of theranostic NPs
until reaching their target site, comprehen-
sion as to what biological entities interact
with the NPs, how their physico-chemical
characteristics may be altered over time
and from interaction with different envi-
ronments, as well as subsequently how
these potential adaptations might affect
the effectiveness of the NPs when they
engage with the intended site of interest is
decidedly necessary. Focus upon these key
aspects would further enable the enhanced
development of theranostic NPs from a
materials’ perspective, allowing them to
be optimized for maximal benefit toward
their proposed application. Through this
approach, significant improvement to the
efficacy of the NPs to the target site would
be obtained concomitantly. Nonetheless,
which route of transport toward the target
site of the applied theranostic NPs should
be studied first?
APPROACHING THE PROBLEM
The main administration route for
most theranostic-based NPs is via intra-
venous injection (Nichols and Bae, 2012).
Thus, the initial biological environment
that these theranostic-based NPs will
encounter is the complex cellular and
molecular milieu of the human blood cir-
culation (as described in Figure 1). Thus,
foremost direction toward understand-
ing its impact upon theranostic NPs is
paramount.
To systematically study the impact
of the bloodstream upon thernostic
NPs, in vivo (i.e., rodents) assessment
would rapidly determine the efficacy of
NPs formulated for theranostics. Yet,
despite encompassing a “whole-body”
scenario, it would not provide species
specificity, which would be necessary
for the inevitable application of NPs
as theranostic agents. Primates would
therefore be ideal, as used in the study by
FIGURE 1 | Schematic of a human blood vessel, representative of the human bloodstream.
Image shows the three main cell types, (i) erythrocytes, also known as red blood cells (RBCs)
(represented as flat, disc-shaped red cells), which contain hemoglobin (an iron-containing
biomolecule responsible for oxygen (O2) binding), (ii) leukocytes (i.e., white blood cells)
(represented as white, round cells) and (iii) thrombocytes (i.e., platelets) (represented as small
purple cells), the essential cell type that allows for blood clotting (Abbas and Lichtman, 2003). The
human bloodstream is responsible for the circulation of nutrients (i.e., amino acids), O2 and
hormones, in addition to the removal of metabolic waste (e.g., carbon dioxide) (Abbas and
Lichtman, 2003). It assists in regulating body temperature and pH, and further engages in the
fighting of disease states. All of these functions contribute toward the essential maintenance of the
homeostasis of the human body. In addition the human bloodstream is suspended within a protein
matrix, abundant in albumin, known as plasma (i.e., blood serum together with fibrinogens) acting
under the influence of non-classical hydrodynamic flow, known as haemodynamics (Abbas and
Lichtman, 2003). The suitability of this holistic environment upon nanoparticles (represented as
gold spheres) for theranostic applications is currently limited.
Ye et al. (2012), who showed the applica-
bility of quantum dots as useful theranos-
tic tools. However, neither in vivo strategy
would provide the basis for a systematic
study as to how NPs may interact with
their numerous local environments (i.e.,
within the bloodstream) prior to arriving
at their intended target site in the human
body. By adopting an in vitro perspec-
tive however, it would enable a controlled
outlook toward studying the impact of
each biological constituent of the human
bloodstream upon the chosen theranos-
tic NPs. Difficulties in this approach arise
however, since it would only allow for
monoculture, or, at the most, co-culture
systems to be used to conduct such inves-
tigations. Although advanced in vitro sys-
tems concerning the bloodstream and its
constituent parts are being established,
such as the advanced platelet model system
recently reported by Thon et al. (2014), a
finite model system that mimics the blood-
stream is currently lacking. Therefore,
currently, to comprehend how biological
environments, such as the bloodstream,
may impact upon the effectiveness of ther-
anostic NPs a combined in vitro and in vivo
approach should be integrated as a vital
component in the development of thera-
nostic NPs.
On an additional note, it is prudent to
note that such a systematic study of any
therapeutic NPs from the specific expo-
sure site, via the potential transport route
to the target site should be performed
in order to gauge their potential effec-
tiveness following administration. In this
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regard, it is also relevant to highlight that
a series of other exposure routes, includ-
ing ingestion, cutaneous and inhalation
(Melancon et al., 2012), the latter for
which theranostic applications are being
derived (Pison et al., 2006), also pose a
potential access route for NPs into the
blood circulation via translocation across
cellular barriers (Kreyling et al., 2012).
Furthermore, the use of NPs to coat
implants (i.e., for antimicrobial purposes)
has recently increased (Kempe et al., 2010),
and therefore it is possible that these
could further concentrate the NPs gain-
ing access into the human bloodstream,
also via barrier cell translocation. Yet, the
presence of NPs within the bloodstream
from these exposure routes represents a
secondary, non-specific exposure scenario
and relates to a risk perspective. Whilst
risk assessment is not the purpose of
this article, it is worth to highlight that
this issue has received limited attention
to date, and requires further, in-depth
investigation which could advantageously
coincide with the advancement of NPs
for nanomedicine-based applications (i.e.,
understanding their biocompatibility).
MOVING FORWARD
Due to the lack of an advanced in vitro
model system, as previously highlighted,
determining the role of each component of
the bloodstream as to its potential impact
upon theranostic NPs is imperative to
their overall development. However which
constituents are important?
Most notably, the immediate and abun-
dant adherence of proteins (as well as
lipids) to the surface of any theranos-
tic NPs entering the bloodstream (Lynch
et al., 2006) can create a possible issue
towards the surface molecules attached
for a specific therapeutic purpose (i.e.,
receptor-binding sequence), as well as a
loss in colloidal stability due to aggregation
(Hirsch et al., 2014). Although NPs with
varying physico-chemical characteristics
can be manipulated for nanotheranos-
tics, it has become abundantly apparent
that similar proteins are consistently found
upon the surface of NPs independent of
their surface coating/charge (Hirsch et al.,
2013). Whilst this is a dynamic process
upon the surface of NPs, there remains a
hard protein layer on top of the NPs at
all times, thus posing a significant issue
to material scientists. Yet, if coated with
abundant proteins, these can engage with
the epitopes on the immune cells, and so
it is difficult to decipher if the steric repul-
sive barrier of a polymer shell would still
remain effective enough to prevent uptake
by these phagocytic cells, or not. Although,
if internalized by the immune system, will
they be processed and potentially exocy-
tosed by these cell types, and exhibit the
same properties prior to their adminis-
tration? What the physico-chemical state
of the NPs is following this interac-
tion is currently unknown, and requires
in-depth investigation. If however, the
immune system does not recognize the
NPs, then there is a heightened possibil-
ity that they could pass, unimpeded into
erythrocytes (Rothen-Rutishauser et al.,
2006). The impact that this cellular inter-
action may have upon the NPs is relatively
unknown. Although if the NPs become
present within these cell types, circulation
time (of the NPs) will most likely increase,
perhaps rendering them ineffective and/or
aggregating within the bloodstream with
potential adverse/fatal consequences in the
long-term. In addition to these cellu-
lar/molecule based issues, the effect of
the injection process (e.g., pressure, flow-
rate, pH and temperature changes) upon
the physico-chemical characteristics of the
NPs via their administration route must
also be conceived. Therefore, increased
research strategies must be directed toward
this approach to achieve the successful
development of theranostic NPs.
OVERALL PERSPECTIVE
Due to their inevitable administration to
the human body via intravenous injec-
tion, understanding of the interaction of
theranostic NPs with the complex bio-
logical environment of the bloodstream
is vital in regards to their development.
The knowledge created from this approach
could enable key understanding to be
gained as to the ability for the NPs
to withstand the confines of this local
environment. Furthermore, it will pro-
vide imperative insight into their abil-
ity to effectively perform the task they
were engineered to achieve (e.g., drug
delivery). Since following this approach
the NPs will most likely require fur-
ther manipulation regarding their physi-
cal and chemical characteristics, in order
to achieve this outlook an enhanced,
multi-interdisciplinary approach must be
adopted. By combining the expertise of
a variety of disciplines it will enable
the advancement of systematic studies of
the physical and chemical state of the
NPs based on the impact observed when
NPs are present within the bloodstream.
Therefore, this perspective will facilitate
the essential development required to suc-
cessfully manufacture effective theranostic
NPs for human health care.
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